Answers are grounded in this paper and cite their sources.
Review reveals methodology and quality of patient-reported outcomes in multi-center transplant trials, highlighting the need for rigorous collection standards.
The Blood and Marrow Transplant Clinical Trials Network performs multi-center Phase 2 and Phase 3 clinical trials and has incorporated patient reported outcome (PRO) measures into study protocols since its inception. As with clinical data, collection and analysis of this type of information requires rigor to allow valid conclusions. This paper summarizes our experience with PROs over the last 25 years and reports on the quality of PRO reporting as well as lessons learned in this academic network setting.
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: